These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 9412924)

  • 21. Nonsteroidal antiinflammatory drug induced hypersensitivity vasculitis clinically mimicking temporal arteritis.
    Lie JT; Dixit RK
    J Rheumatol; 1996 Jan; 23(1):183-5. PubMed ID: 8838531
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Inhibitory effects of the cyclooxygenase-2 inhibitor, etodolac, on colitis-associated tumorigenesis in p53-deficient mice treated with dextran sulfate sodium.
    Mukawa K; Fujii S; Tominaga K; Yoshitake N; Abe A; Kono T; Sekikawa A; Fukui H; Ichikawa K; Tomita S; Imura J; Ono Y; Shinoda M; Hiraishi H; Fujimori T
    Oncol Rep; 2008 Feb; 19(2):393-9. PubMed ID: 18202786
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Nabumetone, an effective anti-inflammatory agent, lacks gastrointestinal irritancy in the rat when dosed orally for one month: comparison with tiaprofenic acid and etodolac.
    Melarange R; Gentry C; Blower PR; Toseland CD; Spangler R
    Eur J Rheumatol Inflamm; 1994; 14(2):15-22. PubMed ID: 7744129
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evaluation of adverse effects of long-term oral administration of carprofen, etodolac, flunixin meglumine, ketoprofen, and meloxicam in dogs.
    Luna SP; Basílio AC; Steagall PV; Machado LP; Moutinho FQ; Takahira RK; Brandão CV
    Am J Vet Res; 2007 Mar; 68(3):258-64. PubMed ID: 17331014
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparative efficacy of etodolac and placebo in rheumatoid arthritic patients.
    Vetter G; Placchi M; Joubert L
    Int J Clin Pharmacol Ther Toxicol; 1982 May; 20(5):240-5. PubMed ID: 6212555
    [TBL] [Abstract][Full Text] [Related]  

  • 26. An overview of the efficacy of etodolac in arthritic disorders.
    Bacon PA
    Eur J Rheumatol Inflamm; 1990; 10(1):22-34. PubMed ID: 2146130
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The gastroduodenal effects of buffered aspirin, carprofen, and etodolac in healthy dogs.
    Reimer ME; Johnston SA; Leib MS; Duncan RB; Reimer DC; Marini M; Gimbert K
    J Vet Intern Med; 1999; 13(5):472-7. PubMed ID: 10499732
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The enantiomers of etodolac, a racemic anti-inflammatory agent, play different roles in efficacy and gastrointestinal safety.
    Inoue N; Nogawa M; Ito S; Tajima K; Kume S; Kyoi T
    Biol Pharm Bull; 2011; 34(5):655-9. PubMed ID: 21532152
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Gastrointestinal blood loss in arthritic patients receiving chronic dosing with etodolac and piroxicam.
    Jallad NS; Sanda M; Salom IL; Perdomo CS; Garg DC; Mullane JF; Weidler DJ
    Am J Med Sci; 1986 Nov; 292(5):272-6. PubMed ID: 2946224
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Damages to the large intestine induced by non-steroidal anti-inflammatory agents].
    Brenna E; Sandvik AK; Kleveland PM; Waldum HL
    Tidsskr Nor Laegeforen; 1995 Apr; 115(10):1225-7. PubMed ID: 7754489
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evaluation of etodolac in subjects with renal impairment.
    Brater DC
    Eur J Rheumatol Inflamm; 1990; 10(1):44-55. PubMed ID: 2146131
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Histopathologic evaluation of the effects of etodolac in established adjuvant arthritis in rats: evidence for reversal of joint damage.
    Weichman BM; Chau TT; Rona G
    Arthritis Rheum; 1987 Apr; 30(4):466-70. PubMed ID: 2953342
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Anti-inflammatory effects of etodolac: comparison with other non-steroidal anti-inflammatory drugs.
    Inoue K; Fujisawa H; Motonaga A; Inoue Y; Kyoi T; Ueda F; Kimura K
    Biol Pharm Bull; 1994 Dec; 17(12):1577-83. PubMed ID: 7735198
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The pharmacokinetics of etodolac in serum and synovial fluid of patients with arthritis.
    Kraml M; Hicks DR; McKean M; Panagides J; Furst D
    Clin Pharmacol Ther; 1988 May; 43(5):571-6. PubMed ID: 2966693
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Double-blind, parallel-group evaluation of etodolac and naproxen in patients with acute sports injuries.
    D'Hooghe M
    Clin Ther; 1992; 14(4):507-16. PubMed ID: 1388091
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Intestinal side effects of COX-2 inhibitors].
    Calvo N; Iversen E; Munck LK
    Ugeskr Laeger; 2006 Mar; 168(13):1343-4. PubMed ID: 16579892
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effectiveness and safety of etodolac in treatment of rheumatoid arthritis: a multicentre two-months' open study.
    Puccetti L; Soletti A; Petrini G; Remorini E; Zuccotti M; Bazzichi L; Ciompi ML
    Int J Clin Pharmacol Res; 1990; 10(6):347-53. PubMed ID: 2151575
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Safety profile of etodolac in the elderly population.
    Bacon PA
    Eur J Rheumatol Inflamm; 1994; 14(1):19-22. PubMed ID: 7744124
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Neutropenia does not prevent etodolac- or indomethacin-induced gastrointestinal damage in the rat.
    Melarange R; Gentry C; Toseland CD; Smith PH; Fuller J
    Dig Dis Sci; 1995 Dec; 40(12):2694-703. PubMed ID: 8536533
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Allergic vasculitis caused by etodolac. The first case].
    Willemin B; Blickle JF; Meaume S; Zerbe S; Brogard JM
    Ann Med Interne (Paris); 1989; 140(6):529-30. PubMed ID: 2533855
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.